Any growth factor showed no clear difference in adverse events (non‐serious and serious) compared with placebo or no growth factor (low certainty).
Summary of findings: dopamine agonists leads to higher number of dropouts due to adverse events compared with placebo (high certainty).
Paracetamol (single oral dose, any dose or formulation; subgroups up… showed no clear difference in patients with one or more adverse events compared with placebo; GRADE not reported.
It is very uncertain whether pharmacological interventions changes adverse events: death (secondary outcome) compared with placebo (very low certainty).
It is very uncertain whether scaling and root planing (SRP) plus antibiotics (amoxicillin and… changes adverse events due to periodontal therapy compared with supragingival scaling (plus placebo) (very low certainty).
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
Summary of findings for multi‐dose nasal decongestant showed no clear difference in secondary outcome: all adverse eventsOral compared with placebo (low certainty).
procaine may leads to higher total adverse events in "healthy" persons compared with placebo (low certainty).
It is very uncertain whether testosterone changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
Hydrocortisone showed no clear difference in dropouts due to adverse events at 3 months compared with placebo (low certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (moderate certainty).
Remdesivir and standard care showed no clear difference in adverse events (any grade) at up to day 28 compared with standard care (plus/minus placebo) (low certainty).
RBD‐specific polyclonal F(ab') 2 fragments of equine antibodies… led to higher adverse events at grade 3 or 4 (by day 28) compared with saline placebo; GRADE not reported.
Casirivimab/imdevimab showed no clear difference in adverse events: all grades within 6 months compared with placebo (low certainty).
Casirivimab/imdevimab showed no clear difference in serious adverse events until data cut‐offb compared with placebo (low certainty).
Tixagevimab/cilgavimab showed no clear difference in adverse events: all grade within 6 monthsb compared with placebo (low certainty).
It is very uncertain whether carisbamate changes treatment withdrawal due to adverse events compared with placebo (very low certainty).
The review found no eligible studies for this question.